Mercado U, Arzola E, Sepúlveda R

Language: Spanish
References: 25
Page: 827-833
PDF size: 207.63 Kb.

ABSTRACT

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (Wegener), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss), necrotizing and crescentic glomerulonephritis that lacked well defined immunoglobulin deposit and drug-induced vasculitides. The five phenotypes are characterized by small vessel vasculitis, absence or paucity of vessel wall localization of immunoglobulin and complement, with or without granulomatous inflammation, most often in the lung, and the presence of circulating ANCA with specificity toward proteinase-3 or myeloperoxidase. The mechanism by which ANCAs cause vasculitis is unknown. Experimental and clinical evidence suggest that both PR-3 and MPO proteases are pathogenic. Traditionally, Fauci regimen of GPA consists of daily oral cyclophosphamide and glucorticoids. Other therapies include rituximab, plasmapheresis and mycophenolate.

REFERENCES

1. Alarcón-Segovia D. Classification of the necrotizing vasculitides in man. Clin Rheum Dis 1980; 6: 223-31. https://doi. org/10.1016/S0307-742X(21)00294-0.

2. Jennette, JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.

3. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: posible arbovirus aetiology? Br Med J 1982; 285: 606. doi: 10.1136/bmj.285.6342.606.

4. Hall JB, Wadham BM, Wood CJ, Ashton V, Adam WR. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust N Z J Med 1984; 14:277-8. doi: 10.1111/j.1445-5994.1984.tb03769.x.

5. Van der Woude FJ, Rassmusen N, Lobato S, Wiikk A, Permin H, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985; 1: 425-29. doi: 10.1016/s0140-6736(85)91147-x.

6. Nakazawa D, Masuda S, Tomaru U, Ishizo A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. At Rev Rheumatol 2019; 15: 91-101. doi: 10.1038/ s41584-018-0145-y.

7. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006; 6: 541-50. doi: 10.1038/nri1841.

8. Geetha D, Jefferson JA. ANCA-associated vasculitis: Core Curriculum 2020. Am J Kidney Dis 2019; 75: 124-137. doi: 10.1053/j.ajkd.2019.04.031.

9. Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suarez LF, Guillevin L, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017; 13: 683-692. doi: 10.1038/ nrrheum.2017.140.

10. Mercado U. Wegener’s granulomatosis: The man behind the eponym. Cleve Clin J Med 1994; 61: 428-30. doi: 10.3949/ccjm.61.6.428.

11. Mercado U. Seventy-five years of microscopic polyangiitiswhat have we learned? J Rheumatol 1999;10: 2081-2.

12. Mercado U. La primera descripción clínica de la granulomatosa con poliangitis (antes granulomatosis de Wegener). Rev Med Inst Mex Seguro Soc 2017; 55: 380-1.

13. Hidalgo VS, Silva AP, Undurraga SF, Soto IN, Marinovic MMA. Vasculitis ANCA-positivo en pacientes hipertiroideos usua- rios de propiltiouracilo. Rev Med Chile 2006; 134: 475-80. http://dx.doi.org/10.4067/S0034-98872006000400011.

14. Bilge NS, Kasifoglu T, Kork C. PTU-induced ANCA-positive vasculitis: an innocent or a life-threatening adverse effect? Rheumatol Int 2013; 33: 117-20. doi: 10.1007/s00296- 011-2280-5.

15. Birck R, Schmitt WH, Kaelsch IA, Van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23. doi: 10.1053/j. ajkd.2005.09.022.

16. Falk R, Hoffman GS. Controversies in small vessel vasculitis-comparing the rheumatology and nephrology views. Curr Opin Rheumatol 2007; 19: 1-9. doi: 10.1097/ BOR.0b013e328011cb80.

17. Miloslavsky EM, Lu Na, Unizony S, Choi HK, Merkel PA, Seo P, et al. Myeloperoxidase-anti-neutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener’s). Arthritis Rheumatol 2016; 68: 2945-2952. doi: 10.1002/art.39812.

18. Schirmer JH, Wright MN, Herrmann K, Laudien M, Nolle B, Reinhold-Keller E, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis. A retrospective analysis of 315 patients from a German Vasculitis Center. Arthritis Rheumatol 2016; 68: 2953-2963. doi: 10.1002/art.39786.

19. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963. doi: 10.1172/ JCI15918.

20. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary -renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 4: 758-61.

21. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidaseantineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93: 398-401. doi: 10.1016/S1081- 1206(10)61400-7.

22. Silva F, Spechs U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of anti-myeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis.2009; 54:542-545.

23. Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973; 52: 535-61.

24. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232. doi: 10.1056/NEJMoa0909905.

25. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220. DOI: 10.1056/ NEJMoa0909169.